(Q35105056)

6 August 2017

1 reference

title

Paraneoplastic neurologic syndromes. (English)

1 reference

6 August 2017

2

Josep Dalmau

1 reference

6 August 2017

Luis Bataller

1

1 reference

6 August 2017

publication date

1 February 2003

1 reference

6 August 2017

1 reference

6 August 2017

volume

21

1 reference

6 August 2017

issue

1

1 reference

6 August 2017

page(s)

221-47, ix

1 reference

Neurological paraneoplastic syndromes in patients with small cell lung cancer. A prospective survey of 150 patients

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Myasthenia gravis in patients with thymoma, with particular reference to onset after thymectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Carcinomatous neuromuscular syndromes. A clinical and quantitative electrophysiological study

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Peripheral neuropathy and myopathy associated with carcinoma of the lung.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Paraneoplastic neurologic syndromes: pathogenesis and physiopathology

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Tumor-specific killer cells in paraneoplastic cerebellar degeneration

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Motor neuron syndromes in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Ganglionitis in paraneoplastic subacute sensory neuronopathy: a morphologic study

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

T-cell receptor analysis in anti-Hu associated paraneoplastic encephalomyelitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Cell-mediated autoimmunity in paraneoplastic neurological syndromes with anti-Hu antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Cytotoxic T cells react with recombinant Yo protein from a patient with paraneoplastic cerebellar degeneration and anti-Yo antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Cytotoxic T lymphocyte-mediated cell death in paraneoplastic sensory neuronopathy with anti-Hu antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Clinical outcome of patients with anti-Hu-associated encephalomyelitis after treatment of the tumor

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Molecular and clinical diversity in paraneoplastic immunity to Ma proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Frequency and clinical correlates of anti-neural IgM antibodies in neuropathy associated with IgM monoclonal gammopathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Paraneoplastic vasculitis of the peripheral nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

[18F]fluorodeoxyglucose positron emission tomography in the diagnosis of cancer in patients with paraneoplastic neurological syndrome and anti-Hu antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

The role of [18F]fluoro-2-deoxyglucose-PET scanning in the diagnosis of paraneoplastic neurological disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Peripheral neuropathies associated with monoclonal proteins: a clinical review

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Do titin and cytokine antibodies in MG patients predict thymoma or thymoma recurrence?

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Utility of anti-Hu antibodies in the diagnosis of paraneoplastic sensory neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Detection of the anti-Hu antibody in the serum of patients with small cell lung cancer?A quantitative western blot analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Nervous system lupus mimics limbic encephalitis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Human herpesvirus 6 limbic encephalitis after stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Encephalomyelitis with carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Epilepsia partialis continua: a new manifestation of anti-Hu-associated paraneoplastic encephalomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Sub-acute cerebellar degeneration with anti-Yo autoantibodies: immunohistochemical analysis of the immune reaction in the central nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Inflammatory infiltrates and complete absence of Purkinje cells in anti-Yo-associated paraneoplastic cerebellar degeneration.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Localization of the neuronal antigen recognized by anti-Tr antibodies from patients with paraneoplastic cerebellar degeneration and Hodgkin's disease in the rat nervous system.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal autoantibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Immunological and pathological study of anti-Ri-associated encephalopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Long-term neurologic outcome in children with opsoclonus-myoclonus associated with neuroblastoma: a report from the Pediatric Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies-a report from the Children's Cancer Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

NEUROMUSCULAR DISORDERS ASSOCIATED WITH MALIGNANT NEOPLASTIC DISEASE

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Diagnosis of progressive multifocal leucoencephalopathy by PCR detection of JC virus from CSF

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Two cases of necrotizing myelopathy associated with malignancy caused by herpes simplex virus type 2.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Acute ascending necrotizing myelopathy caused by herpes simplex virus type 2.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Paraneoplastic motor neuron disease and renal cell carcinoma: improvement after nephrectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Lymphoma, motor neuron diseases, and amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Motor neuron disease and amyotrophic lateral sclerosis: relation of high CSF protein content to paraproteinemia and clinical syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Stiff-man syndrome updated

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Autoimmunity to gephyrin in Stiff-Man syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Autoantibodies to a 128-kd synaptic protein in three women with the stiff-man syndrome and breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Autoantibodies to GABA-ergic neurons and pancreatic beta cells in stiff-man syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Stiff-man syndrome with vacuolar degeneration of anterior horn motor neurons

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Paraneoplastic peripheral neuropathy associated with anti‐Hu antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Anti-Hu-associated paraneoplastic sensory neuropathy responding to early aggressive immunotherapy: report of two cases and review of literature

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Carcinoma associated paraneoplastic peripheral neuropathies in patients with and without anti-onconeural antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Nerve and muscle microvasculitis in peripheral neuropathy: a remote effect of cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Prevalence of monoclonal protein in peripheral neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

The neuropathy of multiple myeloma. An electrophysiological and histological study

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Osteosclerotic myeloma and peripheral neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Polyneuropathy, skin hyperpigmentation, edema, and hypertrichosis in localized osteosclerotic myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

The Crow-Fukase syndrome: a study of 102 cases in Japan

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Myeloma neuropathy. Successful treatment of two patients and review of cases

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Long-term clinical and neurophysiological follow-up of patients with peripheral, neuropathy associated with benign monoclonal gammopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Waldenström's macroglobulinemia: clinical features, complications, and management

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Neuropathy and IgM paraproteinemia: differential binding of IgM M-proteins to peripheral nerve glycolipids

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Peripheral neuropathy associated with IgM monoclonal gammopathy: correlations between M-protein antibody activity and clinical/electrophysiological features in 40 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Peripheral nerve damage during multiple myeloma and Waldenstrom's macroglobulinemia: an ultrastructural and immunopathologic study

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Treatment of polyneuropathy in Waldenstrom's macroglobulinemia: Role of paraproteinemia and immunologic studies

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Prognosis of neuropathy with monoclonal gammopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Plasma exchange and chlorambucil in polyneuropathy associated with monoclonal IgM gammopathy. IgM-associated Polyneuropathy Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Successful treatment of IgM paraproteinaemic neuropathy with fludarabine

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Non-Hodgkin malignant lymphomas and peripheral neuropathies—13 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Severe polyneuropathy: Initial manifestation of Castleman's disease associated with POEMS syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Chronic relapsing neuropathy associated with Castleman's disease (angiofollicular lymph node hyperplasia)

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Peripheral neuropathy associated with Castleman's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Epidemiological features of Guillain-Barré syndrome in Sweden, 1978-93

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Guillain-Barré syndrome in the elderly. A retrospective comparative study

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Guillain-Barré syndrome and Hodgkin's disease: three cases with immunological studies

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Role of therapeutic plasmapheresis in the acute Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Paralytic brachial neuritis in Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Paraneoplastic Brachial Plexopathy in a Patient With Hodgkin's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

A SYNDROME OF CONTINUOUS MUSCLE-FIBRE ACTIVITY

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Immunological associations of acquired neuromyotonia (Isaacs' syndrome). Report of five cases and literature review

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Acquired neuromyotonia: evidence for autoantibodies directed against K+ channels of peripheral nerves

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Potassium channel antibodies in two patients with reversible limbic encephalitis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Multiple paraneoplastic diseases associated with thymoma

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

The Lambert-Eaton myasthenic syndrome. A review of 50 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Autonomic dysfunction in the Lambert-Eaton myasthenic syndrome: serologic and clinical correlates

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Electromyography and electric stimulation of nerves in diseases of motor unit; observations on myasthenic syndrome associated with malignant tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Lambert-eation myasthenic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Lambert-Eaton myasthenic syndrome: clinical diagnosis, immune-mediated mechanisms, and update on therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

The effect of myasthenic syndrome antibody on presynaptic calcium channels in the mouse

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Autoimmune aetiology for myasthenic (Eaton-Lambert) syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Incidence of serum anti-P/O-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Trends in the association of Lambert-Eaton myasthenic syndrome with carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

A treatment algorithm for Lambert-Eaton myasthenic syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Treatment of Lambert-Eaton syndrome with intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

3,4-Diaminopyridine (DAP) in the treatment of Lambert-Eaton myasthenic syndrome (LEMS).

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Lambert-Eaton myasthenic syndrome (LEMS). Clinical and electrodiagnostic features and response to therapy in 59 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Wide spectrum of symptomatic treatment in Lambert-Eaton myasthenic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Plasmapheresis and immunosuppressive drug therapy in the Eaton-Lambert syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

1 reference

7 January 2021

Myasthenic Antibodies Cross-Link Acetylcholine Receptors to Accelerate Degradation

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

The relationship between thymus and oncogenesis. A study of the incidence of non thymic malignancy in myasthenia gravis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Polymyositis, dermatomyositis and inclusion-body myositis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Abnormalities of gastric and esophageal emptying in polymyositis and dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

MR imaging in amyopathic dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Case Report: amyopathic dermatomyositis associated with transformed malignant lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Cardiac abnormalities in polymyositis/dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Pulmonary disease in polymyositis/dermatomyositis: a clinicopathological analysis of 65 autopsy cases

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Microvascular deposition of complement membrane attack complex in dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Vascular Deposits of Immunoglobulin and Complement in Idiopathic Inflammatory Myopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Idiopathic inflammatory myopathies

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Paraneoplastic necrotizing myopathy: clinical and pathological features

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Necrotizing myopathy with pipestem capillaries, microvascular deposition of the complement membrane attack complex (MAC), and minimal cellular infiltration

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Acute rhabdomyolysis after concurrent administration of interleukin-2, interferon-alfa, and chemotherapy for metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

Paraneoplastic syndromes of the spinal cord, nerve, and muscle

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2802%2900037-3

7 January 2021

10.1016/S0733-8619(02)00037-3

Identifiers

DOI

1 reference

6 August 2017

1 reference